Argenx SE (NASDAQ:ARGX) Reports Strong Q1 2025 Results, Slightly Misses Estimates
Argenx SE (NASDAQ:ARGX), a global immunology company, reported robust financial results for the first quarter of 2025, ending March 31, 2025. The company posted an adjusted earnings per share (EPS) of $2.58, slightly below the consensus estimate of $2.75, with a net income per share of $2.78. Total operating income reached $807 million, driven by $790 million in global product net sales, narrowly missing the expected $799.22 million but reflecting a 99% year-over-year growth.
 
Argenx, listed on both Euronext and NASDAQ under the symbol ARGX, focuses on developing innovative therapies for severe autoimmune diseases. Its flagship product, VYVGART, and its subcutaneous form, VYVGART Hytrulo, have been key drivers of growth. The company competes with other biotech firms in the immunology space, aiming to deliver transformative treatments to patients worldwide.
 
A significant milestone in Q1 2025 was the U.S. launch of the VYVGART Hytrulo pre-filled syringe for self-injection, approved by the FDA on April 10, 2025, for generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The product is now available in the U.S. and Germany, with initial patients treated. Additionally, the Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for VYVGART-SC (available as both vial and pre-filled syringe) for CIDP in the European Union, with a European Commission decision expected by June 2025.
 
Financially, Argenx maintains a strong position, supported by a cash balance of approximately $3.4 billion as of Q3 2024, reflecting minimal debt and a high current ratio indicative of liquidity to cover short-term liabilities. CEO Tim Van Hauwermeiren emphasized the company’s commitment to its “Vision 2030” strategy, which aims to reach 50,000 patients across 10 labeled indications by 2030. The Q1 2025 results, including a shift from a net loss to profitability, underscore progress toward this goal.
 
Argenx hosted a conference call on May 8, 2025, at 2:30 PM CET (8:30 AM ET) to discuss these results and provide further updates. While the company’s high valuation reflects investor confidence, its focus on innovation and expansion positions it well for future growth in the competitive biotech landscape.